idarucizumab Injection [Praxbind]

RE-VERSE AD, a prospective multicentric cohort study, examined the effect of idarucizumab on 2 cohorts of patients anticoagulated… Expand

Idarucizumab is a humanized monoclonal antibody fragment engineered to specifically neutralize the effects of the oral direct… Expand

Although clinical trials have shown that bleeding rates associated with the use of target-specific oral anticoagulant drugs are… Expand

Dabigatran, an oral anticoagulant that acts by inhibiting thrombin, was first marketed in the European Union in 2008. No antidote… Expand

ABSTRACT The number of novel antibody therapeutics that received first marketing approvals in 2015 met expectations, with 6… Expand

La mise sur le marche des anticoagulants oraux directs (AOD) a multiplie les patients traites au long cours par ces molecules… Expand

Idarucizumab (Praxbind®) is a fully humanized, monoclonal antibody fragment developed by Boehringer Ingelheim as a specific… Expand

espanolSe resenan los medicamentos evaluados y con dictamen positivo por comision de expertos de la Agencia Espanola de… Expand